Xenter has raised $58.25 million in Series B funding to support the commercial launch of its diagnostics business, expand manufacturing capacity and advance its wireless medical devices and AI-enabled healthcare intelligence platform.
The financing closed on June 30 and included participation from existing shareholders, family offices and healthcare investors. Xenter said the investors share its vision of transforming how clinical data is captured, connected and used across hospitals and physicians’ offices.
The company plans to use the proceeds to launch XenFi, continue developing its proprietary medical technologies and accelerate the expansion of its integrated TechMed platform.
Additional funding will support clinical studies, regulatory programs and manufacturing initiatives as Xenter moves several technologies toward broader commercial use.
Xenter describes itself as a TechMed company operating at the intersection of medical devices, healthcare data infrastructure and clinical artificial intelligence.
Its platform is designed to connect medical devices, diagnostics and digital health systems through a wireless ecosystem that captures what Xenter calls Physical Intelligence data.
Physical Intelligence refers to high-fidelity clinical, physiological, procedural and diagnostic information generated directly during patient care. Xenter aims to collect and organize that information in real time so it can support clinical decisions, future product development and AI-powered analysis.
The company believes healthcare providers continue to rely on disconnected medical devices and fragmented information systems that make it difficult to combine data across a patient’s care journey.
Medical equipment may generate valuable information during a procedure, but that data can remain isolated within individual devices or separate hospital systems. Xenter is developing an integrated infrastructure layer intended to connect those sources and make the information more usable.
The XenFi wireless ecosystem is central to that strategy. It is being designed to connect medical devices and diagnostic technologies while securely transmitting clinical data across Xenter’s broader platform.
Xenter expects the platform’s data library to expand with each procedure. Over time, the accumulated information could help healthcare providers identify clinical patterns, improve diagnostic accuracy and develop more personalized approaches to treatment.
The company also intends for patients to retain control over their healthcare data as it moves through the ecosystem.
A major near-term priority is the commercial launch of Xenter’s diagnostics business unit. The financing will give the company additional resources to establish manufacturing, regulatory, sales and operational capabilities needed to bring its technologies to healthcare providers.
Xenter will also use the Series B funding to begin planned clinical testing of Guru, its dual-sensor physiology guidewire, in transcatheter aortic valve replacement procedures.
TAVR is a minimally invasive procedure used to replace an aortic valve that has become narrowed and can no longer function properly. Physicians guide a replacement valve to the heart through a blood vessel rather than performing traditional open-heart surgery.
The Guru guidewire is being developed to collect physiological information during these procedures. Xenter believes more precise, real-time data could help clinicians evaluate patients and make better-informed procedural decisions.
The company will need to complete applicable clinical and regulatory processes before the device can be broadly commercialized.
Beyond Guru, Xenter is developing additional wireless medical devices and technologies capable of generating data for its Physical Intelligence platform.
The company’s strategy is to build both the hardware that captures clinical information and the software infrastructure that organizes and analyzes it. This integrated approach could reduce the difficulty of connecting devices from separate vendors and transferring information between clinical systems.
Xenter believes access to standardized, high-quality data will be essential for expanding the use of artificial intelligence in healthcare.
AI systems depend on reliable and contextually useful information. In clinical environments, incomplete or inconsistent data can limit the effectiveness of predictive models and decision-support tools.
By capturing information directly from connected medical devices, Xenter aims to provide AI systems with a more accurate view of what occurs during procedures and diagnostic evaluations.
The platform could eventually support healthcare organizations seeking to analyze outcomes, compare procedural techniques, identify operational inefficiencies and improve clinical protocols.
Xenter was founded in 2020 by life sciences entrepreneur Richard J. Linder and is headquartered in Draper, Utah.
Along with the financing, Xenter appointed Linda Vega to its board of directors.
Vega brings experience in banking, finance, corporate governance and strategic capital planning. She previously served as an executive at Wachovia Bank and has advised organizations ranging from emerging companies to multinational enterprises.
Her experience includes financial strategy, capital formation, governance and long-term value creation.
Xenter expects Vega to help guide the company as it deploys the Series B capital, expands commercial operations and advances its medical technologies through clinical and regulatory development.
The company said her appointment adds financial and accounting expertise to a board that includes experienced leaders from the life sciences and medical industries.
The financing represents an important step as Xenter transitions from platform and product development toward commercialization.
Building connected medical technologies requires coordination across engineering, software development, clinical testing, regulatory compliance and manufacturing. The new funding will allow Xenter to expand these functions while preparing its diagnostics business for market entry.
The company’s longer-term goal is to create an intelligence layer that connects clinical data across the continuum of care.
By combining wireless medical devices, diagnostic technologies and AI-powered analysis, Xenter aims to give patients, physicians and healthcare systems access to more timely and actionable information.
KEY QUOTES:
“The closing of Series B strongly validates Xenter’s wireless Physical Intelligence platform and enables the first commercial launch of our diagnostics business unit and the initiation of planned clinical testing of the Guru dual-sensor physiology guidewire in Transcatheter Aortic Valve Replacement procedures. This financing represents more than capital; it reflects the confidence our investors have in our long-term vision to fundamentally change how healthcare technologies communicate, generate data and improve patient outcomes. Healthcare has historically been built around disconnected devices and computers on wheels with fragmented information systems. Xenter is building an integrated intelligence platform designed to connect medical devices, diagnostics, digital health and AI into a seamless ecosystem that enables better clinical decision-making while continually ensuring patients control their healthcare data. Linda’s experience guiding organizations through periods of significant growth and capital deployment will provide tremendous value as Xenter continues its next phase of expansion. Her financial expertise and strategic perspective will strengthen our Board as we continue executing our long-term vision.”
Richard J. Linder, Founder, Chairman and CEO of Xenter
“It’s a great honor to be appointed to Xenter’s Board of Directors, a board that consists of some of the most experienced and legendary leaders in life sciences and medicine. I hope to bring my experience in business, finance and accounting to an already world-class board of directors.”
Linda Vega, Board Member at Xenter
